Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Item

http://www.wikidata.org/entity/Q34442510

Q34442510

about

New players in the preventive treatment of migraine CGRP as a neuropeptide in migraine: lessons from mice Headache management: pharmacological approaches Neurovascular contributions to migraine: Moving beyond vasodilation Minority Representation in Migraine Treatment Trials.Anti-CGRP monoclonal antibodies in migraine: current perspectives.Migraine: multiple processes, complex pathophysiology.Therapeutic antibodies against CGRP or its receptor A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation A second trigeminal CGRP receptor: function and expression of the AMY1 receptor.Taking the headache out of migraine.Nociception-specific blink reflex: pharmacology in healthy volunteers Preventive Migraine Treatment.The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points.Metabotropic glutamate receptor 5: a target for migraine therapy.Efficacy of (S)-Lacosamide in preclinical models of cephalic pain.Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms.Calcitonin gene-related peptide and pain: a systematic review.The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.Clinical trials update 2014: year in review.Emerging drugs for migraine treatment.CGRP mechanism antagonists and migraine management.Emerging treatments for the primary headache disorders.Targeting CGRP: A New Era for Migraine Treatment.Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.The role of anti-CGRP antibodies in the pathophysiology of primary headaches.Update on the Pharmacological Treatment of Chronic Migraine.An update on migraine: current understanding and future directions.New treatments for headache.CGRP in human models of primary headaches.Post-Traumatic Headache Therapy in the Athlete.Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.Chronic migraine treatment: from OnabotulinumtoxinA onwards.Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies.Pathophysiology of Migraine: A Disorder of Sensory Processing.CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?

P2860

Q26778185-D3C821CA-4AEE-4F20-A5FD-F7874D879508 Q26821821-BD32EC04-9D35-48D5-A7C2-BF5BF91EFF48 Q27316751-1B5B88EE-85D5-49C0-9A3A-AADC19800F29 Q28392631-132194F8-9D4F-42C2-8E5C-A2489BCE1F1D Q30238764-ECF16B10-08CE-4776-B579-D30A6D6D108D Q34531880-1AA61822-43E9-4D54-815B-026A36B326E6 Q35547845-A5FDBEEA-1E8D-48F7-B4EC-2283A0D9F5B3 Q35684794-8CC000CE-FF05-45C9-9774-C3A1710C8948 Q35693015-B121BE1A-7FA2-4BB0-978A-3CCECB4DC733 Q35777253-754FB931-3244-4801-BA8B-969806A2F7E7 Q35996556-2F7BB536-2508-48DD-98ED-12C1B22124DC Q36137719-7490F198-BB3D-4CA8-BA90-547D9D5D13BF Q36267944-F1928301-2C1E-462E-A5C0-6EEFFEF93845 Q36340711-D7E49755-6093-428B-8DEA-BF379638131D Q37063451-35D3705A-D403-4DC3-957C-55784F735FD1 Q37208487-70E79E21-37A1-454B-837E-76292B22F505 Q37451570-DE25DC8D-26E3-4779-930B-ABCEE8ABF84E Q37558868-E3EDACC7-5665-418E-B0E3-CE1EC6C51A16 Q37707191-07597ED4-A4CB-4B5E-967B-49A557D01DD8 Q37713262-D9A33EA5-0220-4E07-87DB-33836DBB7FB2 Q38293380-550EB895-33B3-44CE-8148-FA779A461B1B Q38303376-0549FB5B-A50C-414C-B66A-B71C8B293173 Q38384223-AE074E5D-0E0D-43B8-B4B9-41532DDC35DB Q38504746-C492268F-9F93-4372-BBA4-5A41F0BFF9FC Q38542176-84346466-60F4-4B9F-B67F-41934FAA81BA Q38575679-452CC1DA-EF6B-43D9-959A-24CFD9426AAE Q38665422-C57ADF10-2F6B-4CFB-A39C-CE9E004CCB0D Q38681565-8FA45FBD-F06C-438B-8FA3-AAC92F436C99 Q38686130-C293B3EB-38FE-43DB-95FA-2B7F8A83BC8C Q38742593-432959D5-7DE4-403D-B7FE-84B8CC93707E Q38773593-B5EA436A-C78F-4D36-AF99-52E79E9F3BA6 Q38784420-09A64573-134F-4BB5-88DB-05DB1CC10AFA Q38835485-5C4A1975-E45D-4C90-8C22-64CA6285F779 Q38855312-1064D642-03F0-4FA8-AC39-B56877512B2F Q38866988-782DA798-AC7B-43B8-88FD-F293337EF9D9 Q39026796-EC5321CA-AF3F-4DBF-BDDE-68119604E381 Q39127073-983FC3DD-D7C8-4FFC-ACB1-2065A146FCB4 Q39193269-E3D0F842-5208-450C-A271-914360328B61 Q39242677-CE6998C0-F2E2-4CCD-B056-2441ABAA942F Q39400059-13A6CE0C-771F-45FD-B901-E415D9518C16

P2860

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Item

http://www.wikidata.org/entity/Q34442510

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue